Toca­gen shares col­lapse as in­ves­ti­ga­tors read last rites for PhI­II brain can­cer study

Two years af­ter go­ing pub­lic on the promise of a new ap­proach to fight re­cur­rent brain can­cer, Toca­gen has hit the wall.

The biotech …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.